- Home
- FDMT vs ADCT Comparison
FDMT vs ADCT Comparison
Compare FDMT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | ADCT |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.4M | 439.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FDMT | ADCT |
|---|---|---|
| Price | $7.98 | $3.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $34.29 | $7.60 |
| AVG Volume (30 Days) | ★ 747.3K | 565.6K |
| Earning Date | 02-27-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $120,000.00 | ★ $75,209,000.00 |
| Revenue This Year | $21,227.03 | $12.48 |
| Revenue Next Year | $161.87 | $5.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 605.88 | 6.35 |
| 52 Week Low | $2.24 | $1.05 |
| 52 Week High | $12.34 | $4.80 |
Technical Indicators
Market Signals| Indicator | FDMT | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 46.33 |
| Support Level | $7.30 | $3.48 |
| Resistance Level | $7.80 | $3.87 |
| Average True Range (ATR) | 0.53 | 0.21 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 55.27 | 37.25 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).